Published in BJU Int on August 27, 2010
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer (2014) 2.26
Notch in the kidney: development and disease. J Pathol (2011) 1.08
Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. BMC Cancer (2013) 1.05
Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients? Onco Targets Ther (2014) 0.78
Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett (2017) 0.75
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2010) 7.70
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol (2008) 7.30
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Genes that distinguish physiological and pathological angiogenesis. Cancer Cell (2007) 3.35
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol (2012) 3.30
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2006) 2.80
Microvesicles as mediators of intercellular communication in cancer--the emerging science of cellular 'debris'. Semin Immunopathol (2011) 2.78
Microvesicles: messengers and mediators of tumor progression. Cell Cycle (2009) 2.66
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A (2009) 2.66
Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J (2011) 2.50
A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A (2002) 2.16
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell (2013) 1.93
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab (2013) 1.81
Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology (2002) 1.67
Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci U S A (2006) 1.54
Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer (2002) 1.49
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47
Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys (2002) 1.45
Active surveillance for prostate cancer. JAMA (2010) 1.44
GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier. Proc Natl Acad Sci U S A (2011) 1.41
TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell (2012) 1.34
Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol (2012) 1.34
Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst (2013) 1.32
Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res (2009) 1.27
A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging (2014) 1.21
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood (2012) 1.20
New technologies for the detection of circulating tumour cells. Br Med Bull (2010) 1.20
Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol (2011) 1.20
Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol (2006) 1.15
Re: editorial comment on focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study (lancet oncol 2012; 13: 622-632). J Urol (2012) 1.15
Oncogenic extracellular vesicles in brain tumor progression. Front Physiol (2012) 1.15
Active surveillance, quality of life, and cancer-related anxiety. Eur Urol (2013) 1.14
Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology (2002) 1.14
Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood (2010) 1.14
Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol (2010) 1.13
MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology (2012) 1.13
Large-scale identification of novel transcripts in the human genome. Genome Res (2007) 1.13
MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. Urology (2010) 1.12
Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer (2008) 1.12
Mutations in ANTXR1 cause GAPO syndrome. Am J Hum Genet (2013) 1.11
Dietary fat and prostate cancer. J Urol (2004) 1.10
Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res (2005) 1.10
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res (2008) 1.09
Calculation of quantum-mechanical descriptors for QSPR at the DFT level: is it necessary? J Chem Inf Model (2008) 1.09
Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.08
Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. Phys Med Biol (2009) 1.07
Active surveillance for low-risk prostate cancer: an update. Nat Rev Urol (2011) 1.05
Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J (2003) 1.04
Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol (2010) 1.03
The cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeleton. Biochim Biophys Acta (2010) 1.01
Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology (2002) 1.00
Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol (2011) 1.00
Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R. Cancer Res (2004) 0.99
Acute management of priapism in men. BJU Int (2012) 0.98
Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol (2012) 0.98
Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci U S A (2013) 0.95
The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thromb Res (2007) 0.95
Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol (2010) 0.95
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochem Biophys Res Commun (2010) 0.95
Tissue factor and cancer. Pathophysiol Haemost Thromb (2009) 0.95
Stabilization of very rare tautomers of uracil by an excess electron. Phys Chem Chem Phys (2005) 0.94
Stabilization of very rare tautomers of 1-methylcytosine by an excess electron. J Phys Chem A (2005) 0.94
MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapy. J Magn Reson Imaging (2013) 0.93
Genetic pathways linking hemostasis and cancer. Thromb Res (2012) 0.93
Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol (2011) 0.93
Peripheral primitive neuroectodermal tumor arising from the seminal vesicle. Urol Int (2008) 0.92
Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A (2014) 0.91
Acquisition of anoikis resistance promotes the emergence of oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumorigenicity in vivo. Neoplasia (2007) 0.91
Selective blockade of tumor angiogenesis. Cell Cycle (2012) 0.91
Photoelectron spectroscopy of adiabatically bound valence anions of rare tautomers of the nucleic acid bases. J Chem Phys (2007) 0.91
Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem (2012) 0.91
Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost (2004) 0.90
Presolvated low energy electron attachment to peptide methyl esters in aqueous solution: C-O bond cleavage at 77 K. J Phys Chem B (2013) 0.90
Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol (2002) 0.90
The burden of prostate cancer in Canada. Can Urol Assoc J (2009) 0.90
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res (2005) 0.89
Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr Cancer (2010) 0.89
A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther (2013) 0.88
Tissue factor and cancer stem cells: is there a linkage? Arterioscler Thromb Vasc Biol (2009) 0.87
On the unusual stability of valence anions of thymine based on very rare tautomers: A computational study. J Phys Chem B (2006) 0.87
Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer. Eur Urol (2012) 0.87
Valence anions of N-acetylproline in the gas phase: computational and anion photoelectron spectroscopic studies. J Chem Phys (2011) 0.87
Essential regulation of lung surfactant homeostasis by the orphan G protein-coupled receptor GPR116. Cell Rep (2013) 0.86
Interaction with glycine increases stability of a mutagenic tautomer of uracil. A density functional theory study. J Am Chem Soc (2005) 0.86
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology (2002) 0.86
Urothelial carcinoma of the prostate. Urology (2007) 0.86
Cardiovascular effects of androgen depletion and replacement therapy. Urology (2006) 0.85
Recovery of erectile function after unilateral and bilateral cavernous nerve interposition grafting during radical pelvic surgery. J Urol (2009) 0.84